ストックスクリーナーアプリを入手
92.54
0.55%
0.51
アフターアワーズ：
92.54
前日終値:
$92.03
開ける：
$93.25
24時間の取引高:
1.68M
Relative Volume:
0.86
時価総額：
$18.42B
収益：
$5.14B
当期純損益:
$1.29B
株価収益率:
14.45
EPS:
6.4034
ネットキャッシュフロー:
$1.33B
1週間 パフォーマンス:
-3.54%
1か月 パフォーマンス:
-8.47%
6か月 パフォーマンス:
+11.36%
1年 パフォーマンス:
+36.67%
1日の値動き範囲:
$91.28
$93.64
1週間の範囲:
$91.28
$97.86
52週間の値動き範囲:
$53.56
$112.29
Incyte Corp Stock (INCY) Company Profile
Compare INCY vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
92.54 | 18.42B | 5.14B | 1.29B | 1.33B | 6.4034 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-05 | 開始されました | H.C. Wainwright | Buy |
| 2026-01-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | アップグレード | Mizuho | Neutral → Outperform |
| 2025-11-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2025-10-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | 開始されました | Barclays | Overweight |
| 2025-06-16 | アップグレード | Stifel | Hold → Buy |
| 2025-03-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-18 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 開始されました | UBS | Neutral |
| 2024-10-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-01 | 開始されました | Wolfe Research | Outperform |
| 2024-09-18 | ダウングレード | Truist | Buy → Hold |
| 2024-07-02 | ダウングレード | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 開始されました | Deutsche Bank | Hold |
| 2024-04-23 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 開始されました | Jefferies | Buy |
| 2024-02-14 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-11-21 | ダウングレード | Goldman | Buy → Neutral |
| 2023-07-25 | 開始されました | Citigroup | Buy |
| 2023-05-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-04-10 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 開始されました | Piper Sandler | Overweight |
| 2022-08-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-08-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-07-28 | 開始されました | Wells Fargo | Equal Weight |
| 2022-02-09 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-07-20 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-02-10 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 開始されました | Truist | Buy |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-06-16 | 開始されました | The Benchmark Company | Hold |
| 2020-05-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 再開されました | William Blair | Outperform |
| 2020-03-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 再開されました | BofA/Merrill | Neutral |
| 2020-01-03 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2020-01-03 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-10-03 | 開始されました | Mizuho | Buy |
| 2019-09-12 | 開始されました | BMO Capital Markets | Market Perform |
| 2019-09-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-09-05 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 開始されました | Credit Suisse | Neutral |
| 2019-05-03 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 開始されました | Stifel | Hold |
| 2019-04-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | アップグレード | William Blair | Mkt Perform → Outperform |
すべてを表示
Incyte Corp (INCY) 最新ニュース
European Commission Approves J&J Prostate Drug, PLX Fabry Dosing, Incyte's Zynyz Second Indication - RTTNews
Incyte (INCY) Down 4.2% Since Last Earnings Report: Can It Rebound? - finance.yahoo.com
Incyte (INCY): Buy, Sell, or Hold Post Q4 Earnings? - finance.yahoo.com
Incyte Advances New Early Stage Drug INCA033989 Into Human Testing - TipRanks
Incyte at Barclays Conference: Navigating Post-Jakafi Future - Investing.com
Russell Investments Group Ltd. Has $68.44 Million Stock Position in Incyte Corporation $INCY - MarketBeat
Korea Investment CORP Raises Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Incyte at Leerink Global Healthcare Conference: Strategic Growth Focus - Investing.com
Incyte Corporation $INCY Shares Purchased by Vestcor Inc - MarketBeat
INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz - Finviz
Incyte becomes third company to receive CRL over issues at Novo Indiana factory - Endpoints News
Stifel reiterates Incyte stock rating after FDA setback - Investing.com
Incyte (NASDAQ:INCY) Receives Buy Rating from HC Wainwright - MarketBeat
WINTON GROUP Ltd Acquires 213,557 Shares of Incyte Corporation $INCY - MarketBeat
A Glimpse Into The Expert Outlook On Incyte Through 13 Analysts - Benzinga
INCY: Today's Analyst Rating Update by HC Wainwright & Co. | INC - GuruFocus
Incyte wins EC approval of Zynyz for SCAC - The Pharmaletter
Meiji Yasuda Asset Management Co Ltd. Has $2.34 Million Stock Position in Incyte Corporation $INCY - MarketBeat
Sun Pharma launches Leqselvi in US; settles litigation with Incyte Corp - MSN
Incyte Corporation $INCY Stake Reduced by Vinva Investment Management Ltd - MarketBeat
Assessing Incyte (INCY) Valuation After EC Approval Of Zynyz For Advanced Anal Cancer - simplywall.st
FDA Declines New Indication for Incyte's (INCY) Zynyz Due to Man - GuruFocus
Incyte fails to win FDA label expansion for cancer therapy due to issues at Novo plant - Seeking Alpha
Incyte (INCY) Gains EC Approval for Combination Therapy with Zyn - GuruFocus
Incyte Corporation (INCY) Receives FDA Complete Response Letter for Zynyz® sBLA - GuruFocus
FDA issues complete response letter for Incyte’s Zynyz application in lung cancer - Investing.com
Assessing Incyte (INCY) Valuation After Recent Share Price Weakness And Mixed Fair Value Signals - Yahoo Finance
FDA issues CRL for Incyte sBLA for Zynyz in NSCLC over third-party facility inspection - TradingView
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) - ChartMill
Incyte Momentum Builds With Strong Cash Flows Ahead Of Key Conference - finance.yahoo.com
Today's Analyst Rating Update on Incyte (INCY): Evercore ISI Gro - GuruFocus
Incyte Corporation $INCY Shares Bought by Victory Capital Management Inc. - MarketBeat
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
INCY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Teachers Retirement System of The State of Kentucky Has $30.18 Million Stake in Incyte Corporation $INCY - MarketBeat
INCY Earnings History & Surprises | EPS & Revenue Results | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte at TD Cowen Conference: Strategic Growth Beyond Jakafi By Investing.com - Investing.com Canada
Incyte at TD Cowen Conference: Strategic Growth Beyond Jakafi - Investing.com
LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata - Finviz
TD Asset Management Inc Increases Position in Incyte Corporation $INCY - MarketBeat
Incyte to Present at Three March Investor Conferences - MyChesCo
Incyte (INCY) Valuation Check After EMA Boost For Olumiant Alopecia Approval Potential - simplywall.st
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Lilly and Incyte’s Olumiant Recommended in EU for Adolescents with Severe Alopecia Areata - Contract Pharma
Hair-loss pill helps 42% of teens regrow scalp hair in Lilly trial - Stock Titan
Andra AP fonden Boosts Stake in Incyte Corporation $INCY - MarketBeat
NICE backs approval for Incyte’s Opzelura - The Pharma Letter
Incyte Earnings Underscore Shift From Jakafi Reliance To Broader Pipeline - Yahoo Finance
INCYTE (INCY) R&D president exercises options, sells 18,668 shares at $100.91 - Stock Titan
Does Incyte’s 2025 Beat And 2026 Guidance Shift The Bull Case For INCY? - Yahoo Finance
Incyte Corp (INCY) 財務データ
収益
当期純利益
現金流量
EPS
0.48%
1.21%
大文字化:
|
ボリューム (24 時間):